139 related articles for article (PubMed ID: 37407421)
1. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM
Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421
[TBL] [Abstract][Full Text] [Related]
2. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
[TBL] [Abstract][Full Text] [Related]
3. Luminophore Chemistry for Detection of Urinary Bladder Cancer - Comparison to Cytology and Urinary Rapid Tests (BTA stat
Ecke TH; Scislowski M; Hassan N; Saura M; Hallmann S; Koch S; Vuolle S; Malakoutikhah M; Kopra K; Härmä H
Anticancer Res; 2022 Nov; 42(11):5249-5256. PubMed ID: 36288849
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.
Ritter R; Hennenlotter J; Kühs U; Hofmann U; Aufderklamm S; Blutbacher P; Deja A; Hohneder A; Gerber V; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2014 Apr; 32(3):337-44. PubMed ID: 24332643
[TBL] [Abstract][Full Text] [Related]
5. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
6. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
7. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of sensitivity to blood in the urine for urine-based point-of-care assays (UBC rapid, NMP22 BladderChek and BTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on the results of urine-based POC tests.
Lüdecke G; Pilatz A; Hauptmann A; Bschleipfer T; Weidner W
Anticancer Res; 2012 May; 32(5):2015-8. PubMed ID: 22593481
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
11. Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer.
Ecke TH; Arndt C; Stephan C; Hallmann S; Lux O; Otto T; Ruttloff J; Gerullis H
Anticancer Res; 2015 May; 35(5):2651-5. PubMed ID: 25964541
[TBL] [Abstract][Full Text] [Related]
12. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
13. [Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].
Sánchez-Carbayo M; Urrutia M; Hernández-Cerceño ML; González de Buitrago JM; Navajo JA
Med Clin (Barc); 2000 Mar; 114(10):361-6. PubMed ID: 10786344
[TBL] [Abstract][Full Text] [Related]
14. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer.
Oge O; Atsü N; Sahin A; Ozen H
Scand J Urol Nephrol; 2000 Dec; 34(6):349-51. PubMed ID: 11195897
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
[TBL] [Abstract][Full Text] [Related]
17. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
18. Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status.
Boman H; Hedelin H; Jacobsson S; Holmäng S
J Urol; 2002 Nov; 168(5):1955-9. PubMed ID: 12394684
[TBL] [Abstract][Full Text] [Related]
19. [Tumor marker tests in bladder cancer].
Feil G; Stenzl A
Actas Urol Esp; 2006 Jan; 30(1):38-45. PubMed ID: 16703728
[TBL] [Abstract][Full Text] [Related]
20. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
